Human Growth Hormone Drugs - Global Strategic Business Report 2017-2022 Featuring Eli Lilly and Company, Ferring, Genentech, GeneScience Pharmaceuticals & Merck - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Human Growth Hormone Drugs - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million.

The report profiles 28 companies including many key and niche players such as

  • Eli Lilly and Company (US)
  • Ferring Holding SA (Switzerland)
  • Genentech, Inc. (US)
  • GeneScience Pharmaceuticals Co., Ltd. (China)
  • Merck KgaA (Germany)
  • Novo Nordisk A/S (Denmark)
  • Pfizer, Inc. (US)
  • Sandoz International GmbH (Germany)

Key Topics Covered:


  • Market Outlook
  • Evolution of Recombinant Human Growth Hormones (hGH)
  • List of Select Approved Prescription Daily-dose hGH Products by Indication
  • Patent Expiry Paves Way for the Emergence of Biosimilars; Impact Remains Small
  • Strong Innovation Drive Takes Hold of the hGH Industry
  • Sizing the Market
  • Key Growth Drivers
  • High Prevalence of Growth Hormone Deficiency Disorders
  • Innovations Hold the Key to Market Growth
  • New Indications for hGH Replacement Therapy
  • Major Growth Restraining Factors
  • Complex Delivery System
  • High Cost of hGH Treatment
  • Difficulty in Securing Reimbursement
  • Biosimilars Threaten Revenue Growth Erosion
  • Limited Pharmacological Differences Exist Among Current Agents


  • Pediatric GHD Rules, while Adult GHD Remains Underserved
  • Long-Acting hGH Drugs
  • a Potential Game Changer
  • Select Long-Acting hGH Products in Pipeline by Development Stage
  • Biosimilars Create Little Impact, Further Validation to Expand Indications and Growth
  • Manufacturers Bet on Novel Drug Delivery Technologies
  • Phase IV Studies Necessitated for First Biosimilars
  • Needle-less Drug Delivery Systems to Wipe Out of Syringes
  • Drug Delivery Device Options for Marketed hGH Products
  • Growing Non-Prescription/Off-Label Usage
  • A Potential Health Hazard
  • Oral hGH Secretagogues
  • An Alternative to Controversial hGH Injections in Professional Sports
  • Risk of Cancer Necessitates Judicious Use of hGH in Children
  • Dose Titration
  • A Key to Achieve Enhanced Tolerability
  • Growth Concerns about Prolonged Usage of Growth Hormones


  • hGH
  • A Highly Consolidated Market
  • Overview of Select Leading Marketed hGH Products
  • Norditropin
  • Genotropin
  • Humatrope
  • Saizen
  • Omnitrope
  • the Somatropin Biosimilar
  • Somatropin Biopartners
  • Review of Select hGH Products in Pipeline
  • OPKO's Lagova to be the Earliest of Long-Acting hGHs to Hit the Market
  • Somavaratan Advances Further in Clinical Trials
  • Somapacitan Moves Ahead in Development; Nears Commercial Launch
  • TransCon hGH
  • the Potential Blockbuster hGH Product in Waiting
  • HanAll's Vitatropin


  • Key Factors Controlling Natural hGH Secretion
  • Structure of hGH
  • Functions Performed by hGH in the Human Body
  • Benefits of Adequate hGH
  • Effects of Human Growth Hormone Imbalances
  • Hypopituitarism
  • Evolution of Growth Hormone Replacement Therapy
  • Indications for Exogenous hGH Administration
  • Growth Hormone Deficiency (GHD)
  • Symptoms of Adult Growth Hormone Deficiency
  • Idiopathic Short Stature
  • Noonan Syndrome
  • Prader-Willi Syndrome
  • Turner Syndrome
  • Short Stature Homeobox Gene
  • Small for Gestational Age
  • Chronic Renal Insufficiency
  • Short Bowel Syndrome
  • Other Medical Conditions
  • Off-label Applications
  • Contraindications for Somatropin Therapy
  • Safety Review of hGH Therapy
  • Reported Adverse Effects of Inaccurate rhGH Dosages
  • Risks Involved with Pediatric/Adolescent hGH Replacement Therapy
  • Risks Involved with Adult hGH Replacement Therapy


  • NHI Includes JCR Pharmaceuticals's GROWJECT Liquid hGH Formulations in Reimbursement Listing
  • Ascendis Pharma Commences Phase III Trial on TransCon hGH
  • Teijin Inks License Deal with Versartis for Somavaratan
  • JCR Pharmaceuticals Obtains Japanese MHLW Approval for Growject® Liquid Formulations
  • Merck Dissolves Merck Serono and Merck Millipore Brands, Relaunches Merck Brand
  • EMD Serono and Aeterna Zentaris Finalize Promotional Services Deal for Saizen
  • Versartis Commences Phase II/III Studies for VRS-317 in Japan
  • Ferring Pharmaceuticals Obtains FDA Clearance for Name Change of Growth Hormone
  • Hanmi Introduces Development-Stage Long Acting hGH
  • Novo Nordisk Obtains FDA Approval for Norditropin® FlexPro® Prefilled Pen
  • OPKO and Pfizer Ink Agreement for Development of OPKO's Long- acting hGH-CTP
  • Pfizer Announces Positive Results from Phase 3B Study on Genotropin for SGA in Children



Total Companies Profiled: 28 (including Divisions/Subsidiaries 33)

- The United States (10)

- Canada (1)

- Japan (2)

- Europe (10)

- Germany (4)

- The United Kingdom (2)

- Rest of Europe (4)

- Asia-Pacific (Excluding Japan) (9)

- Middle East (1)

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs


Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs